Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Faulty Protein Interaction Disrupts Neuromuscular Junctions and Triggers ALS

By Gerald M. Slutzky, PhD
Posted on 01 Dec 2016
Humans and mice are protected from developing amyotrophic lateral sclerosis (ALS) by the action of muscle fibers that secrete and concentrate the fibroblast growth factor binding protein 1 (FGFBP1) at neuromuscular junctions.

The FGFBP1 gene encodes a secreted fibroblast growth factor carrier protein, which plays a critical role in cell proliferation, differentiation, and migration by binding to fibroblast growth factors and potentiating their biological effects on target cells.

ALS is a specific disorder that involves the death of neurons. More...
The disease, for which there is no cure, is characterized by stiff muscles, muscle twitching, and gradually worsening weakness due to muscles decreasing in size. Most ALS sufferers die from respiratory failure. The neuromuscular junction (NMJ) is critical for all voluntary movement. Its malformation during development and degeneration during aging or in ALS impairs motor function.

Investigators at the Virginia Tech Carilion Research Institute (Roanoke, VA, USA) reported in the November 14, 2016, online edition of The Journal of Neuroscience that while FGFBP1 expression increased during development, its expression decreased prior to NMJ degeneration during aging and in the SOD1G93A ALS mouse model. FGFBP1 expression was shown to be inhibited by increased accumulation of transforming growth factor-beta1 (TGF-beta1) in skeletal muscles and at their NMJs. When they examined the impact of deleting FGFBP1 on NMJs, the investigators found that in the absence of FGFBP1, NMJs exhibited structural abnormalities in developing and in middle age mice. Deletion of FGFBP1 from SOD1G93A mice also accelerated NMJ degeneration and death.

These findings suggested that targeting the interaction between FGFBP1 and TGF-beta1 signaling could hold promise for slowing age- and disease-related degeneration of NMJs.

"TGF-beta1 is upregulated in ALS and in turn blocks expression of FGFBP1, which is released by muscle fibers to preserve the integrity of the neuromuscular junction," said senior author Dr. Gregorio Valdez, assistant professor of biological sciences at the Virginia Tech Carilion Research Institute. "The body is trying to help itself by generating more TGF-beta1. Unfortunately, TGF-beta1 accumulates at the synapse where it blocks expression of FGFBP1, accelerating degeneration of the neuromuscular junction. Our findings suggest that targeting these molecules may allow these important synapses to stay in place, and slow the progression of ALS."

Related Links:
Virginia Tech Carilion Research Institute


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.